HIF1A and COVID-19: These data explain why the adaptive immune response of diabetic patients after infection with the COVID-19 is weakened, why lung function is impaired, and clearly expose the axis of mitochondrial reactive oxygen species/HIF-1α/glycolysis, suggesting that targeting HIF-1α may be a strategy to develop new drugs for the treatment of COVID-19 [53, 54].